Tirofiban HCl

Tirofiban should be used with caution in patients with hepatic impairment (avoid if severe); renal impairment; major surgery or severe trauma within 3 months (avoid if within 6 weeks); traumatic or protracted cardiopulmonary resuscitation, organ biopsy or lithotripsy within last 2 weeks; risk of bleeding including peptic ulcer within 3 months; acute pericarditis, aortic dissection, haemorrhagicretinopathy, vasculitis, haematuria, faecal occult blood, severe heart failure, cardiogenic shock, anaemia; puncture of non-compressible vessel within 24 hours; concomittant drugs that increase risk of bleeding (including within 48 hours after thrombolytic); monitor platelet count, haemoglobin and haematocrit before treatment, 2-6 hours after start of treatment and then atleast once daily ; discontinue if thrombolytic therapy, intra-aortic balloon pump or emergency cardiac surgery necessary; discontinue immediately if serious bleeding uncontrolled by pressure occurs; pregnancy (use only if potential benefits outweigh risk) .